- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00711594
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
Phase I/II Open Label Trial of Continuous Once Daily Oral Treatment With BIBW 2992 - Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib.
The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dose for the Phase II step.
The objective of the Phase II step is to estimate the efficacy of BIBW 2992 monotherapy in patients with first generation EGFR-TKI-resistant advanced NSCLC at the recommended dose determined in the Phase I step.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Akashi, Hyogo, Japan
- 1200.33.010 Boehringer Ingelheim Investigational Site
-
Chuo-ku, Tokyo, Japan
- 1200.33.001 Boehringer Ingelheim Investigational Site
-
Fukuoka, Fukuoka, Japan
- 1200.33.007 Boehringer Ingelheim Investigational Site
-
Hidaka, Saitama, Japan
- 1200.33.013 Boehringer Ingelheim Investigational Site
-
Kanazawa, Ishikawa, Japan
- 1200.33.011 Boehringer Ingelheim Investigational Site
-
Kashiwa, Chiba, Japan
- 1200.33.003 Boehringer Ingelheim Investigational Site
-
Kobe, Hyogo, Japan
- 1200.33.019 Boehringer Ingelheim Investigational Site
-
Koto-ku, Tokyo, Japan
- 1200.33.008 Boehringer Ingelheim Investigational Site
-
Matsuyama, Ehime, Japan
- 1200.33.020 Boehringer Ingelheim Investigational Site
-
Miyakojima-ku, Osaka, Japan
- 1200.33.006 Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japan
- 1200.33.004 Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japan
- 1200.33.017 Boehringer Ingelheim Investigational Site
-
Niigata, Niigata, Japan
- 1200.33.016 Boehringer Ingelheim Investigational Site
-
Okayama, Okayama, Japan
- 1200.33.009 Boehringer Ingelheim Investigational Site
-
Osaka-Sayama, Osaka, Japan
- 1200.33.005 Boehringer Ingelheim Investigational Site
-
Sakai, Osaka, Japan
- 1200.33.018 Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan
- 1200.33.015 Boehringer Ingelheim Investigational Site
-
Sendai, Miyagi, Japan
- 1200.33.012 Boehringer Ingelheim Investigational Site
-
Sunto-gun, Shizuoka, Japan
- 1200.33.002 Boehringer Ingelheim Investigational Site
-
Yufu, Oita, Japan
- 1200.33.014 Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Phase II step;
- Patients with pathologic confirmation of NSCLC with tissue diagnosis or cytologic diagnosis, whose NSCLCs are locally advanced or metastatic Stage III-B / IV adenocarcinoma, and are inoperable and incurable with radiotherapy.
Patients who have received the following pretreatments for the treatment of relapsed or metastatic NSCLC.
- Patients who have received at least one but not more than two lines of chemotherapy. ("Chemotherapy" means only the first line (doublet chemotherapies including a platinum) and/or the second line (single chemotherapy except for a platinum) of cytotoxic chemotherapy according to the standard chemotherapies, and erlotinib (Tarceva®) and gefitinib (Iressa®) should be excluded. One of the chemotherapy regimens must have been platinum-based. In addition, only one prior cytotoxic chemotherapy treatment regimen is allowed after adjuvant chemotherapy containing a platinum. More than two prior cytotoxic chemotherapy treatment regimens are not allowed.)
- After the above chemotherapies, patients who once got clinical benefits (i.e. complete response, partial response or stable disease) but progressed following at least 12 weeks of treatment with erlotinib (Tarceva®) or gefitinib (Iressa®) as the most recent treatment. ("Clinical benefit" and "progression" should be confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). In addition, "at least 12 weeks of treatment" should be 9 weeks or more as the actual "treatment period except for treatment pause due to adverse events and other reasons.) As long as the treatment is erlotinib or gefitinib monotherapy, patients can receive multiple regimens of either or both treatments, but one of the regimens should be for at least 12 weeks
- Male or female patients age >=20 years at the enrolment.
- Life expectancy of at least three (3) months after the start of administration of the investigational drug.
- Eastern Cooperative Oncology Group (ECOG) performance Score 0 or 1.
- Patients with at least one tumor lesion that can accurately be measured by CT or MRI in at least one dimension with longest diameter to be recorded as no less than double the slice thickness and >=10 mm.
- Written informed consent that is consistent with ICH-GCP guidelines.
Exclusion criteria:
Phase II step;
- Use of erlotinib (Tarceva®) or gefitinib (Iressa®) within two weeks before starting the study medication.
- Patients who have received definitive thoracic radiotherapy with curative intent. Patients who have received radiotherapy or other investigational drugs (non-oncological) within four weeks before enrolment.
- Significant gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease, mal-absorption, or CTCAE Grade >2 diarrhea of any etiology at the enrolment.
- Patients with distinct / suspected pulmonary fibrosis or interstitial lung disease by the chest radiographic findings, or patients with a previous history of.
- Brain tumor, and / or brain metastases, which are symptomatic or requiring treatment at the enrolment.
- Other malignancies diagnosed within the past five years (other than carcinoma in situ of gastric cancer, colon cancer and cervical cancer, and non melanomatous skin cancer).
- History of uncontrolled cardiac disease such as angina or myocardial infarction within the past 6 months at the enrolment, congestive heart failure including New York Heart Association (NYHA) functional classification of 3, or arrhythmia requiring treatment.
- Coelomic fluid retention (such as pleural effusion, ascites or pericardial effusion) requiring treatment.
- Uncontrolled concomitant diseases (e.g. diabetes mellitus, hypertension etc).
- History of serious drug hypersensitivity.
Patients who do not have sufficient baseline organ function and whose laboratory data do not meet the following criteria at the enrolment.11
- Haemoglobin count >=9.0 g/dL
- Absolute neutrophil count (ANC) >=1500 / mm3
- Platelet count >=100 000 / mm3
- Serum creatinine <=1.5 mg/dL
- Total bilirubin <=1.5 mg/dL
- Aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) <=2.5x upper limit of normal range (if related to liver metastases <=2.5x upper limit of normal also)
- PaO2 >=60torr or SpO2 >=92%
- LVEF as measured by echocardiography or multigated blood pool imaging of the heart (MUGA scan) >=50%
- QTc interval <0.47 second
- Patients who disagree with using a medically acceptable method of contraception during the administration of the investigational drug and for at least 6 months after the end of administration.
- Pregnant or breast-feeding women, or women suspected of being pregnant.
- Known positive HBs antigen, HCV antibody, or HIV antibody test.
- Known or suspected active drug or alcohol abuse.
- Other patients judged ineligible for enrolment in the study by the investigator (sub-investigator).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIBW 2992 MA2
Phase I step: Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally.
Escalating doses of BIBW 2992 starting at 20mg daily.
|
Phase I step: Increased dose cohorts from low dose to MTD
Phase I step: Increased dose cohorts from low dose to MTD
Phase I step: Increased dose cohorts from low dose to MTD
|
Experimental: BIBW 2992 QD
Phase II step: Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop.
Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs.
|
Phase II step: This is an open label study.
Patients are treated with BIBW 2992 until disease progression or undue AEs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I Step: Safety of BIBW 2992 Assessed Based on Incidence of Dose Limiting Toxicity (DLT) and Incidence & Intensity of Adverse Events According to CTCAE
Time Frame: start of treatment to end of treatment
|
start of treatment to end of treatment
|
|
Phase II Step: Objective Tumour Response According to Response Evaluation Criteria in Solid Tumours (RECIST)
Time Frame: Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation), up to 41.3 months
|
The objective response (complete response [CR] and partial response [PR]) was defined as determined by the RECIST according to the best response to study treatment.
|
Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation), up to 41.3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I Step: AUC0-24, AUCtau,ss of BIBW 2992 After Multiple Oral Administration
Time Frame: AUC0-24: just before drug administration, 0:30,1:00, 2:00, 3:00, 4:00, 5:00, 7:00, 9:00, 24:00 on Day 1-2 in Course 1; AUCtau,ss: just before drug administration, 0:30,1:00, 2:00, 3:00, 4:00, 5:00, 7:00, 9:00, 24:00, 48:00, 72:00 on Day 28-31 in Course 1
|
area under the concentration-time curve of BIBW 2992 over the time interval 0-24 hours (AUC0-24), Area under the concentration-time curve of Afatinib in plasma at steady state (AUCtau,ss) after multiple oral administration Pharmacokinetic was abbreviated to PK.
|
AUC0-24: just before drug administration, 0:30,1:00, 2:00, 3:00, 4:00, 5:00, 7:00, 9:00, 24:00 on Day 1-2 in Course 1; AUCtau,ss: just before drug administration, 0:30,1:00, 2:00, 3:00, 4:00, 5:00, 7:00, 9:00, 24:00, 48:00, 72:00 on Day 28-31 in Course 1
|
Phase II Step: Clinical Benefit
Time Frame: Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
Clinical benefit was defined as a RECIST assessment of complete response, partial response, or stable disease according to the best response to study treatment as defined in the previous section.
Clinical benefit presented as the disease control.
|
Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
Phase II Step: Time to Objective Response
Time Frame: Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
Number of participants with first response at week 4, 8 and 12, assessed by investigator and independent review.
|
Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
Phase II Step: Duration of Objective Response
Time Frame: Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
Duration of objective response was defined as the time at which RECIST was first met for CR or PR (whichever was first recorded) until the first date that recurrent or progressive disease (PD) was objectively documented.
|
Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
Phase I Step: Summary of Epidermal Growth Factor Receptor (EGFR) Mutation Findings
Time Frame: Screening visit
|
Screening visit
|
|
Phase II Step: Duration of Clinical Benefit
Time Frame: Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
Presented as duration of disease control.
|
Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
Phase II Step: Progression-free Survival (PFS)
Time Frame: Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
PFS was defined as the duration of time from the start of treatment until the day of objective tumour progression confirmed by tumour imaging (PD according to the RECIST) or death.
|
Tumour Assessment were performed at screening 14 days (prior to enrollment), in week 4, week 8, week 12 and in 8-week intervals thereafter, and at the end of trial visit (patients discontinuation) up to 41.3 months
|
Phase II Step: Overall Survival (OS)
Time Frame: from start of treatment until end of follow up, up to 53 months
|
OS was defined as the duration of time from the start of treatment to the time of death.
|
from start of treatment until end of follow up, up to 53 months
|
Phase II Step: Safety of BIBW 2992 as Indicated by Intensity and Incidence of Adverse Events, Graded According to CTCAE
Time Frame: Start of treatment to end of treatment (up to 41.3 months) plus 4 week follow-up
|
outcome data show the number of patients with Adverse events (AE) by intensity and incidence of adverse events, graded according to CTCAE.
|
Start of treatment to end of treatment (up to 41.3 months) plus 4 week follow-up
|
Phase II Step: Maximum CTC Grade During the Trial for Laboratory Parameters, Among Patients Who Experienced an Increase in CTC Grade From Baseline
Time Frame: Start of treatment to end of treatment (up to 41.3 months) plus 4 week follow-up
|
outcome data show the number of patients for the maximum CTC grade during the trial for laboratory parameters, among patients who experienced an increase in CTC Grade
|
Start of treatment to end of treatment (up to 41.3 months) plus 4 week follow-up
|
Phase II Step: Trough Plasma Concentrations of BIBW2992 After Multiple Oral Administration of BIBW 2992: Treatment course1 Day 15
Time Frame: Course 1 Day 15
|
Outcome data show the geometric mean (gMean) of trough plasma concentrations of BIBW 2992 after multiple oral administration of BIBW. The dose determined from the result of the Phase I step (50 mg) will be used. Reduction of dose in accordance to the criteria specified by adverse events to 40 mg or 30 mg was possible. |
Course 1 Day 15
|
Phase II Step: Trough Plasma Concentrations of BIBW2992 After Multiple Oral Administration of BIBW 2992: Treatment course2 Day 1
Time Frame: Course 2 Day 1
|
Outcome data show the gMean of trough plasma concentrations of BIBW 2992 after multiple oral administration of BIBW
|
Course 2 Day 1
|
Phase II Step: Trough Plasma Concentrations of BIBW2992 After Multiple Oral Administration of BIBW 2992: Treatment course2 Day 15
Time Frame: Course 2 Day 15
|
Outcome data show the gMean of trough plasma concentrations of BIBW 2992 after multiple oral administration of BIBW
|
Course 2 Day 15
|
Phase II Step: Summary of EGFR Mutation Findings
Time Frame: Screening visit
|
Screening visit
|
|
Phase I Step: Cmax,Cmax,ss of BIBW 2992 After Multiple Oral Administration
Time Frame: Just before start of the treatment to Course 4 Visit 4R2
|
Just before start of the treatment to Course 4 Visit 4R2
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013 Sep 20;31(27):3335-41. doi: 10.1200/JCO.2012.45.0981. Epub 2013 Jul 1.
- Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol. 2012 Apr;69(4):891-9. doi: 10.1007/s00280-011-1738-1. Epub 2011 Nov 10.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Afatinib
Other Study ID Numbers
- 1200.33
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
Clinical Trials on BIBW 2992 MA2 40mg/day
-
Boehringer IngelheimCompleted
-
University of GuadalajaraCompletedMetabolic Syndrome
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
University of ChicagoNational Cancer Institute (NCI)RecruitingRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral CancerUnited States
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedGliomaUnited States, Canada
-
Boehringer IngelheimCompletedBreast NeoplasmsUnited States, United Kingdom
-
Centre Leon BerardBoehringer IngelheimCompletedHead and Neck Squamous Cell CarcinomaFrance